Biblioteca CRAI Dulce Chacón - Universidad Europea de Madrid

CRAI Library - Madrid
Your cart is empty.
My folder ( items) | My account
Image from Google Jackets

Nanomaterial-based drug delivery carriers for cancer therapy / Tao Feng, Yanli Zhao.

By: Feng, Tao,, autor
Contributor(s): Zhao, Yanli,, autor
Material type: materialTypeLabelE-bookSeries: (SpringerBriefs in Applied Sciences and Technology : Nanotheranostics, 2191-5318).Publisher: Abingdon, Oxon ; New York : Routledge Taylor and Francis Group, 2017Publisher: Singapore : Springer, 2017Copyright date: 2017Description: 1 recurso en línea (62 páginas) : ilustraciones (algunas a color).ISBN: 9789811032998; 9811032998.Subject: AntineoplásicosOnline resources: Acceso a este recurso digital (usuarios Universidad Europea de Madrid)Digital Resources
Contents:
Acknowledgements; Contents; About the Authors; 1 Current Status and Characteristics of Cancer; 1.1 Abnormal Metabolism; 1.2 Abnormal Vasculature; 1.3 Resistance to Anti-proliferative Growth Factors (GFs); 1.4 Unlimited Replicative Potential; 1.5 Immune System Activation and Inflammation; 1.6 Interstitial Pressure; References; 2 Clinical Anticancer Drugs for Cancer Treatment; 2.1 Antimetabolites; 2.2 Antimitotic Agents; 2.3 Alkylating Agents; 2.4 Antitumor Antibiotics; 2.5 Tyrosine Kinase Inhibitors (TKI); 2.6 Cyclin Dependent Kinase (CDK) Inhibitors.
2.7 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors2.8 Histone Deacetyltransferase Inhibitors (HDACi); 2.9 Mitogen-Activated Protein Kinase (MAPK) Kinase (MEK) Inhibitors; 2.10 Serine/Threonine-Protein Kinase B-Raf Inhibitors; 2.11 Mammalian Target of Rapamycin (MTOR) Inhibitors; 2.12 Phosphoinositide 3-Kinase (PI3K) Inhibitors; 2.13 Ribonucleotide Reductase (RNR) Inhibitors; 2.14 DNA Methyltransferase Inhibitors; 2.15 Retinoids; 2.16 Monoclonal Antibodies (MAbs); 2.17 Combination Therapy; References; 3 Nanomaterial-Based Drug Delivery Carriers for Cancer Therapy; 3.1 Introduction.
3.2 Organic Nanomaterials3.2.1 FDA-Approved Liposomes; 3.2.2 Polymer-Based Nanoparticles; 3.2.3 Supramolecular Nanosystems; 3.2.4 Others; 3.3 Inorganic Nanomaterials; 3.3.1 Quantum Dots; 3.3.2 Gold Nanomaterials; 3.3.2.1 Gold Nanoparticles; 3.3.2.2 Gold Nanorods; 3.3.3 Mesoporous Silica Nanoparticles; 3.3.4 Carbon Nanomaterials; 3.3.4.1 Carbon Nanotubes; 3.3.4.2 Graphene; 3.3.4.3 Carbon Dots; 3.3.5 Upconversion Nanoparticles; 3.3.6 Two-Dimensional Nanomaterials; 3.3.7 Others; 3.4 Organic-Inorganic Hybrid Nanomaterials; References; Conclusions.
Abstract: This brief summarizes different types of organic and inorganic nanomaterials for drug delivery in cancer therapy. It highlights that precisely designed nanomaterials will be the next-generation therapeutic agents for cancer treatment.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Collection Call number Status Date due Barcode Item holds
LIBRO-E NO PRÉSTAMO LIBRO-E NO PRÉSTAMO Madrid Digital Acceso Electrónico (UEM) Ciencias de la Salud RC270.8 F464 2017 EB (Browse shelf(Opens below)) Acceso electrónico eBook.20022773
Total holds: 0

SpringerLink Springer Engineering eBooks 2017 English+International

Incluye referencias bibliográficas

Acknowledgements; Contents; About the Authors; 1 Current Status and Characteristics of Cancer; 1.1 Abnormal Metabolism; 1.2 Abnormal Vasculature; 1.3 Resistance to Anti-proliferative Growth Factors (GFs); 1.4 Unlimited Replicative Potential; 1.5 Immune System Activation and Inflammation; 1.6 Interstitial Pressure; References; 2 Clinical Anticancer Drugs for Cancer Treatment; 2.1 Antimetabolites; 2.2 Antimitotic Agents; 2.3 Alkylating Agents; 2.4 Antitumor Antibiotics; 2.5 Tyrosine Kinase Inhibitors (TKI); 2.6 Cyclin Dependent Kinase (CDK) Inhibitors.

2.7 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors2.8 Histone Deacetyltransferase Inhibitors (HDACi); 2.9 Mitogen-Activated Protein Kinase (MAPK) Kinase (MEK) Inhibitors; 2.10 Serine/Threonine-Protein Kinase B-Raf Inhibitors; 2.11 Mammalian Target of Rapamycin (MTOR) Inhibitors; 2.12 Phosphoinositide 3-Kinase (PI3K) Inhibitors; 2.13 Ribonucleotide Reductase (RNR) Inhibitors; 2.14 DNA Methyltransferase Inhibitors; 2.15 Retinoids; 2.16 Monoclonal Antibodies (MAbs); 2.17 Combination Therapy; References; 3 Nanomaterial-Based Drug Delivery Carriers for Cancer Therapy; 3.1 Introduction.

3.2 Organic Nanomaterials3.2.1 FDA-Approved Liposomes; 3.2.2 Polymer-Based Nanoparticles; 3.2.3 Supramolecular Nanosystems; 3.2.4 Others; 3.3 Inorganic Nanomaterials; 3.3.1 Quantum Dots; 3.3.2 Gold Nanomaterials; 3.3.2.1 Gold Nanoparticles; 3.3.2.2 Gold Nanorods; 3.3.3 Mesoporous Silica Nanoparticles; 3.3.4 Carbon Nanomaterials; 3.3.4.1 Carbon Nanotubes; 3.3.4.2 Graphene; 3.3.4.3 Carbon Dots; 3.3.5 Upconversion Nanoparticles; 3.3.6 Two-Dimensional Nanomaterials; 3.3.7 Others; 3.4 Organic-Inorganic Hybrid Nanomaterials; References; Conclusions.

This brief summarizes different types of organic and inorganic nanomaterials for drug delivery in cancer therapy. It highlights that precisely designed nanomaterials will be the next-generation therapeutic agents for cancer treatment.

There are no comments on this title.

to post a comment.
Share